img

Global Myasthenia Gravis Treatment Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Myasthenia Gravis Treatment Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Drug therapy for MG includes(1) acetylcholinesterase inhibitors, (2) immunosuppressants, (3) immunomodulators. Introduce and gradually increase options based on international guidelines and the clinical and immunological characteristics of patients. Surgical treatments include (1) thymectomy, (2) median sternotomy and video-assisted thoracoscopic surgery, etc.
Myasthenia Gravis Treatment report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Myasthenia Gravis Treatment market is projected to reach US$ 2623.5 million in 2029, increasing from US$ 1702 million in 2022, with the CAGR of 6.5% during the period of 2024 to 2029. Demand from Hospital and Specialist Clinic are the major drivers for the industry.
The major factors driving the market growth are increasing prevalence of myasthenia gravis, awareness for early diagnosis of myasthenia gravis, and adoption of new treatment options for myasthenia gravis. Rising prevalence of myasthenia gravis globally is one of the major drivers for the growth of the myasthenia gravis treatment market. For example, according to the Myasthenia Gravis Foundation of America, about 20 out of every 100,000 people in the United States have myasthenia gravis, and the disease is more common in women than men. Furthermore, the incidence of myasthenia gravis is increasing worldwide.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Myasthenia Gravis Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Amneal Pharmaceuticals, Inc.
Astellas Pharma, Inc.
Avadel Pharmaceuticals PLC
Bausch Health Companies Inc.
CSL Behring
CuraVac, Inc.
Argenx SE
GlaxoSmithKline plc
Immunovant, Inc.
Mitsubishi Tanabe Pharma Corp.
Novartis AG
Takeda Pharmaceutical Co., Ltd.
UCB Pharma
AstraZeneca
F. Hoffmann-La Roche Ltd
Segment by Type
Monoclonal Antibodies
Intravenous Immunoglobulin
Other

Segment by Application


Hospital
Specialist Clinic
Other

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Myasthenia Gravis Treatment market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Myasthenia Gravis Treatment, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Myasthenia Gravis Treatment industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Myasthenia Gravis Treatment in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Myasthenia Gravis Treatment introduction, etc. Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Myasthenia Gravis Treatment market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Myasthenia Gravis Treatment Market Overview
1.1 Myasthenia Gravis Treatment Product Overview
1.2 Myasthenia Gravis Treatment Market Segment by Type
1.2.1 Monoclonal Antibodies
1.2.2 Intravenous Immunoglobulin
1.2.3 Other
1.3 Global Myasthenia Gravis Treatment Market Size by Type
1.3.1 Global Myasthenia Gravis Treatment Market Size Overview by Type (2018-2029)
1.3.2 Global Myasthenia Gravis Treatment Historic Market Size Review by Type (2018-2024)
1.3.3 Global Myasthenia Gravis Treatment Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Myasthenia Gravis Treatment Sales Breakdown by Type (2018-2024)
1.4.2 Europe Myasthenia Gravis Treatment Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Myasthenia Gravis Treatment Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Myasthenia Gravis Treatment Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Myasthenia Gravis Treatment Sales Breakdown by Type (2018-2024)
2 Global Myasthenia Gravis Treatment Market Competition by Company
2.1 Global Top Players by Myasthenia Gravis Treatment Sales (2018-2024)
2.2 Global Top Players by Myasthenia Gravis Treatment Revenue (2018-2024)
2.3 Global Top Players by Myasthenia Gravis Treatment Price (2018-2024)
2.4 Global Top Manufacturers Myasthenia Gravis Treatment Manufacturing Base Distribution, Sales Area, Product Type
2.5 Myasthenia Gravis Treatment Market Competitive Situation and Trends
2.5.1 Myasthenia Gravis Treatment Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Myasthenia Gravis Treatment Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Treatment as of 2022)
2.7 Date of Key Manufacturers Enter into Myasthenia Gravis Treatment Market
2.8 Key Manufacturers Myasthenia Gravis Treatment Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Myasthenia Gravis Treatment Status and Outlook by Region
3.1 Global Myasthenia Gravis Treatment Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Myasthenia Gravis Treatment Historic Market Size by Region
3.2.1 Global Myasthenia Gravis Treatment Sales in Volume by Region (2018-2024)
3.2.2 Global Myasthenia Gravis Treatment Sales in Value by Region (2018-2024)
3.2.3 Global Myasthenia Gravis Treatment Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Myasthenia Gravis Treatment Forecasted Market Size by Region
3.3.1 Global Myasthenia Gravis Treatment Sales in Volume by Region (2024-2029)
3.3.2 Global Myasthenia Gravis Treatment Sales in Value by Region (2024-2029)
3.3.3 Global Myasthenia Gravis Treatment Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Myasthenia Gravis Treatment by Application
4.1 Myasthenia Gravis Treatment Market Segment by Application
4.1.1 Hospital
4.1.2 Specialist Clinic
4.1.3 Other
4.2 Global Myasthenia Gravis Treatment Market Size by Application
4.2.1 Global Myasthenia Gravis Treatment Market Size Overview by Application (2018-2029)
4.2.2 Global Myasthenia Gravis Treatment Historic Market Size Review by Application (2018-2024)
4.2.3 Global Myasthenia Gravis Treatment Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Myasthenia Gravis Treatment Sales Breakdown by Application (2018-2024)
4.3.2 Europe Myasthenia Gravis Treatment Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Myasthenia Gravis Treatment Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Myasthenia Gravis Treatment Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Myasthenia Gravis Treatment Sales Breakdown by Application (2018-2024)
5 North America Myasthenia Gravis Treatment by Country
5.1 North America Myasthenia Gravis Treatment Historic Market Size by Country
5.1.1 North America Myasthenia Gravis Treatment Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Myasthenia Gravis Treatment Sales in Volume by Country (2018-2024)
5.1.3 North America Myasthenia Gravis Treatment Sales in Value by Country (2018-2024)
5.2 North America Myasthenia Gravis Treatment Forecasted Market Size by Country
5.2.1 North America Myasthenia Gravis Treatment Sales in Volume by Country (2024-2029)
5.2.2 North America Myasthenia Gravis Treatment Sales in Value by Country (2024-2029)
6 Europe Myasthenia Gravis Treatment by Country
6.1 Europe Myasthenia Gravis Treatment Historic Market Size by Country
6.1.1 Europe Myasthenia Gravis Treatment Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Myasthenia Gravis Treatment Sales in Volume by Country (2018-2024)
6.1.3 Europe Myasthenia Gravis Treatment Sales in Value by Country (2018-2024)
6.2 Europe Myasthenia Gravis Treatment Forecasted Market Size by Country
6.2.1 Europe Myasthenia Gravis Treatment Sales in Volume by Country (2024-2029)
6.2.2 Europe Myasthenia Gravis Treatment Sales in Value by Country (2024-2029)
7 Asia-Pacific Myasthenia Gravis Treatment by Region
7.1 Asia-Pacific Myasthenia Gravis Treatment Historic Market Size by Region
7.1.1 Asia-Pacific Myasthenia Gravis Treatment Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Myasthenia Gravis Treatment Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Myasthenia Gravis Treatment Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Myasthenia Gravis Treatment Forecasted Market Size by Region
7.2.1 Asia-Pacific Myasthenia Gravis Treatment Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Myasthenia Gravis Treatment Sales in Value by Region (2024-2029)
8 Latin America Myasthenia Gravis Treatment by Country
8.1 Latin America Myasthenia Gravis Treatment Historic Market Size by Country
8.1.1 Latin America Myasthenia Gravis Treatment Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Myasthenia Gravis Treatment Sales in Volume by Country (2018-2024)
8.1.3 Latin America Myasthenia Gravis Treatment Sales in Value by Country (2018-2024)
8.2 Latin America Myasthenia Gravis Treatment Forecasted Market Size by Country
8.2.1 Latin America Myasthenia Gravis Treatment Sales in Volume by Country (2024-2029)
8.2.2 Latin America Myasthenia Gravis Treatment Sales in Value by Country (2024-2029)
9 Middle East and Africa Myasthenia Gravis Treatment by Country
9.1 Middle East and Africa Myasthenia Gravis Treatment Historic Market Size by Country
9.1.1 Middle East and Africa Myasthenia Gravis Treatment Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Myasthenia Gravis Treatment Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Myasthenia Gravis Treatment Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Myasthenia Gravis Treatment Forecasted Market Size by Country
9.2.1 Middle East and Africa Myasthenia Gravis Treatment Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Myasthenia Gravis Treatment Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Amneal Pharmaceuticals, Inc.
10.1.1 Amneal Pharmaceuticals, Inc. Company Information
10.1.2 Amneal Pharmaceuticals, Inc. Introduction and Business Overview
10.1.3 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Products Offered
10.1.5 Amneal Pharmaceuticals, Inc. Recent Development
10.2 Astellas Pharma, Inc.
10.2.1 Astellas Pharma, Inc. Company Information
10.2.2 Astellas Pharma, Inc. Introduction and Business Overview
10.2.3 Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Astellas Pharma, Inc. Myasthenia Gravis Treatment Products Offered
10.2.5 Astellas Pharma, Inc. Recent Development
10.3 Avadel Pharmaceuticals PLC
10.3.1 Avadel Pharmaceuticals PLC Company Information
10.3.2 Avadel Pharmaceuticals PLC Introduction and Business Overview
10.3.3 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Products Offered
10.3.5 Avadel Pharmaceuticals PLC Recent Development
10.4 Bausch Health Companies Inc.
10.4.1 Bausch Health Companies Inc. Company Information
10.4.2 Bausch Health Companies Inc. Introduction and Business Overview
10.4.3 Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Bausch Health Companies Inc. Myasthenia Gravis Treatment Products Offered
10.4.5 Bausch Health Companies Inc. Recent Development
10.5 CSL Behring
10.5.1 CSL Behring Company Information
10.5.2 CSL Behring Introduction and Business Overview
10.5.3 CSL Behring Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.5.4 CSL Behring Myasthenia Gravis Treatment Products Offered
10.5.5 CSL Behring Recent Development
10.6 CuraVac, Inc.
10.6.1 CuraVac, Inc. Company Information
10.6.2 CuraVac, Inc. Introduction and Business Overview
10.6.3 CuraVac, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.6.4 CuraVac, Inc. Myasthenia Gravis Treatment Products Offered
10.6.5 CuraVac, Inc. Recent Development
10.7 Argenx SE
10.7.1 Argenx SE Company Information
10.7.2 Argenx SE Introduction and Business Overview
10.7.3 Argenx SE Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Argenx SE Myasthenia Gravis Treatment Products Offered
10.7.5 Argenx SE Recent Development
10.8 GlaxoSmithKline plc
10.8.1 GlaxoSmithKline plc Company Information
10.8.2 GlaxoSmithKline plc Introduction and Business Overview
10.8.3 GlaxoSmithKline plc Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.8.4 GlaxoSmithKline plc Myasthenia Gravis Treatment Products Offered
10.8.5 GlaxoSmithKline plc Recent Development
10.9 Immunovant, Inc.
10.9.1 Immunovant, Inc. Company Information
10.9.2 Immunovant, Inc. Introduction and Business Overview
10.9.3 Immunovant, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Immunovant, Inc. Myasthenia Gravis Treatment Products Offered
10.9.5 Immunovant, Inc. Recent Development
10.10 Mitsubishi Tanabe Pharma Corp.
10.10.1 Mitsubishi Tanabe Pharma Corp. Company Information
10.10.2 Mitsubishi Tanabe Pharma Corp. Introduction and Business Overview
10.10.3 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Products Offered
10.10.5 Mitsubishi Tanabe Pharma Corp. Recent Development
10.11 Novartis AG
10.11.1 Novartis AG Company Information
10.11.2 Novartis AG Introduction and Business Overview
10.11.3 Novartis AG Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Novartis AG Myasthenia Gravis Treatment Products Offered
10.11.5 Novartis AG Recent Development
10.12 Takeda Pharmaceutical Co., Ltd.
10.12.1 Takeda Pharmaceutical Co., Ltd. Company Information
10.12.2 Takeda Pharmaceutical Co., Ltd. Introduction and Business Overview
10.12.3 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Products Offered
10.12.5 Takeda Pharmaceutical Co., Ltd. Recent Development
10.13 UCB Pharma
10.13.1 UCB Pharma Company Information
10.13.2 UCB Pharma Introduction and Business Overview
10.13.3 UCB Pharma Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.13.4 UCB Pharma Myasthenia Gravis Treatment Products Offered
10.13.5 UCB Pharma Recent Development
10.14 AstraZeneca
10.14.1 AstraZeneca Company Information
10.14.2 AstraZeneca Introduction and Business Overview
10.14.3 AstraZeneca Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.14.4 AstraZeneca Myasthenia Gravis Treatment Products Offered
10.14.5 AstraZeneca Recent Development
10.15 F. Hoffmann-La Roche Ltd
10.15.1 F. Hoffmann-La Roche Ltd Company Information
10.15.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview
10.15.3 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
10.15.4 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Products Offered
10.15.5 F. Hoffmann-La Roche Ltd Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Myasthenia Gravis Treatment Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Myasthenia Gravis Treatment Industrial Chain Analysis
11.4 Myasthenia Gravis Treatment Market Dynamics
11.4.1 Myasthenia Gravis Treatment Industry Trends
11.4.2 Myasthenia Gravis Treatment Market Drivers
11.4.3 Myasthenia Gravis Treatment Market Challenges
11.4.4 Myasthenia Gravis Treatment Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Myasthenia Gravis Treatment Distributors
12.3 Myasthenia Gravis Treatment Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Monoclonal Antibodies
Table 2. Major Company of Intravenous Immunoglobulin
Table 3. Major Company of Other
Table 4. Global Myasthenia Gravis Treatment Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Myasthenia Gravis Treatment Sales by Type (2018-2024) & (K Units)
Table 6. Global Myasthenia Gravis Treatment Sales Market Share in Volume by Type (2018-2024)
Table 7. Global Myasthenia Gravis Treatment Sales by Type (2018-2024) & (US& Million)
Table 8. Global Myasthenia Gravis Treatment Market Share in Value by Type (2018-2024)
Table 9. Global Myasthenia Gravis Treatment Price by Type (2018-2024) & (US$/Unit)
Table 10. Global Myasthenia Gravis Treatment Sales by Type (2024-2029) & (K Units)
Table 11. Global Myasthenia Gravis Treatment Sales Market Share in Volume by Type (2024-2029)
Table 12. Global Myasthenia Gravis Treatment Sales by Type (2024-2029) & (US$ Million)
Table 13. Global Myasthenia Gravis Treatment Sales Market Share in Value by Type (2024-2029)
Table 14. Global Myasthenia Gravis Treatment Price by Type (2024-2029) & (US$/Unit)
Table 15. North America Myasthenia Gravis Treatment Sales by Type (2018-2024) & (K Units)
Table 16. North America Myasthenia Gravis Treatment Sales by Type (2018-2024) & (US$ Million)
Table 17. Europe Myasthenia Gravis Treatment Sales (K Units) by Type (2018-2024)
Table 18. Europe Myasthenia Gravis Treatment Sales by Type (2018-2024) & (US$ Million)
Table 19. Asia-Pacific Myasthenia Gravis Treatment Sales (K Units) by Type (2018-2024)
Table 20. Asia-Pacific Myasthenia Gravis Treatment Sales by Type (2018-2024) & (US$ Million)
Table 21. Latin America Myasthenia Gravis Treatment Sales (K Units) by Type (2018-2024)
Table 22. Latin America Myasthenia Gravis Treatment Sales by Type (2018-2024) & (US$ Million)
Table 23. Middle East and Africa Myasthenia Gravis Treatment Sales (K Units) by Type (2018-2024)
Table 24. Middle East and Africa Myasthenia Gravis Treatment Sales by Type (2018-2024) & (US$ Million)
Table 25. Global Myasthenia Gravis Treatment Sales by Company (2018-2024) & (K Units)
Table 26. Global Myasthenia Gravis Treatment Sales Share by Company (2018-2024)
Table 27. Global Myasthenia Gravis Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 28. Global Myasthenia Gravis Treatment Revenue Share by Company (2018-2024)
Table 29. Global Market Myasthenia Gravis Treatment Price by Company (2018-2024) & (US$/Unit)
Table 30. Global Myasthenia Gravis Treatment Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Myasthenia Gravis Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Treatment as of 2022)
Table 33. Date of Key Manufacturers Enter into Myasthenia Gravis Treatment Market
Table 34. Key Manufacturers Myasthenia Gravis Treatment Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Myasthenia Gravis Treatment Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 37. Global Myasthenia Gravis Treatment Sales by Region (2018-2024) & (K Units)
Table 38. Global Myasthenia Gravis Treatment Sales Market Share in Volume by Region (2018-2024)
Table 39. Global Myasthenia Gravis Treatment Sales by Region (2018-2024) & (US$ Million)
Table 40. Global Myasthenia Gravis Treatment Sales Market Share in Value by Region (2018-2024)
Table 41. Global Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 42. Global Myasthenia Gravis Treatment Sales by Region (2024-2029) & (K Units)
Table 43. Global Myasthenia Gravis Treatment Sales Market Share in Volume by Region (2024-2029)
Table 44. Global Myasthenia Gravis Treatment Sales by Region (2024-2029) & (US$ Million)
Table 45. Global Myasthenia Gravis Treatment Sales Market Share in Value by Region (2024-2029)
Table 46. Global Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 47. Global Myasthenia Gravis Treatment Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 48. Global Myasthenia Gravis Treatment Sales by Application (2018-2024) & (K Units)
Table 49. Global Myasthenia Gravis Treatment Sales Market Share in Volume by Application (2018-2024)
Table 50. Global Myasthenia Gravis Treatment Sales by Application (2018-2024) & (US$ Million)
Table 51. Global Myasthenia Gravis Treatment Sales Market Share in Value by Application (2018-2024)
Table 52. Global Myasthenia Gravis Treatment Price by Application (2018-2024) & (US$/Unit)
Table 53. Global Myasthenia Gravis Treatment Sales by Application (2024-2029) & (K Units)
Table 54. Global Myasthenia Gravis Treatment Sales Market Share in Volume by Application (2024-2029)
Table 55. Global Myasthenia Gravis Treatment Sales by Application (2024-2029) & (US$ Million)
Table 56. Global Myasthenia Gravis Treatment Sales Market Share in Value by Application (2024-2029)
Table 57. Global Myasthenia Gravis Treatment Price by Application (2024-2029) & (US$/Unit)
Table 58. North America Myasthenia Gravis Treatment Sales by Application (2018-2024) (K Units)
Table 59. North America Myasthenia Gravis Treatment Sales by Application (2018-2024) & (US$ Million)
Table 60. Europe Myasthenia Gravis Treatment Sales by Application (2018-2024) (K Units)
Table 61. Europe Myasthenia Gravis Treatment Sales by Application (2018-2024) & (US$ Million)
Table 62. Asia-Pacific Myasthenia Gravis Treatment Sales by Application (2018-2024) (K Units)
Table 63. Asia-Pacific Myasthenia Gravis Treatment Sales by Application (2018-2024) & (US$ Million)
Table 64. Latin America Myasthenia Gravis Treatment Sales by Application (2018-2024) (K Units)
Table 65. Latin America Myasthenia Gravis Treatment Sales by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Myasthenia Gravis Treatment Sales by Application (2018-2024) (K Units)
Table 67. Middle East and Africa Myasthenia Gravis Treatment Sales by Application (2018-2024) & (US$ Million)
Table 68. North America Myasthenia Gravis Treatment Sales by Country (2018-2024) & (K Units)
Table 69. North America Myasthenia Gravis Treatment Sales Market Share in Volume by Country (2018-2024)
Table 70. North America Myasthenia Gravis Treatment Sales by Country (2018-2024) & (US$ Million)
Table 71. North America Myasthenia Gravis Treatment Sales Market Share in Value by Country (2018-2024)
Table 72. North America Myasthenia Gravis Treatment Sales by Country (2024-2029) & (K Units)
Table 73. North America Myasthenia Gravis Treatment Sales Market Share in Volume by Country (2024-2029)
Table 74. North America Myasthenia Gravis Treatment Sales by Country (2024-2029) & (US$ Million)
Table 75. North America Myasthenia Gravis Treatment Sales Market Share in Value by Country (2024-2029)
Table 76. Europe Myasthenia Gravis Treatment Sales by Country (2018-2024) & (K Units)
Table 77. Europe Myasthenia Gravis Treatment Sales Market Share in Volume by Country (2018-2024)
Table 78. Europe Myasthenia Gravis Treatment Sales by Country (2018-2024) & (US$ Million)
Table 79. Europe Myasthenia Gravis Treatment Sales Market Share in Value by Country (2018-2024)
Table 80. Europe Myasthenia Gravis Treatment Sales by Country (2024-2029) & (K Units)
Table 81. Europe Myasthenia Gravis Treatment Sales Market Share in Volume by Country (2024-2029)
Table 82. Europe Myasthenia Gravis Treatment Sales by Country (2024-2029) & (US$ Million)
Table 83. Europe Myasthenia Gravis Treatment Sales Market Share in Value by Country (2024-2029)
Table 84. Asia-Pacific Myasthenia Gravis Treatment Sales by Region (2018-2024) & (K Units)
Table 85. Asia-Pacific Myasthenia Gravis Treatment Sales Market Share in Volume by Region (2018-2024)
Table 86. Asia-Pacific Myasthenia Gravis Treatment Sales by Region (2018-2024) & (US$ Million)
Table 87. Asia-Pacific Myasthenia Gravis Treatment Sales Market Share in Value by Region (2018-2024)
Table 88. Asia-Pacific Myasthenia Gravis Treatment Sales by Region (2024-2029) & (K Units)
Table 89. Asia-Pacific Myasthenia Gravis Treatment Sales Market Share in Volume by Region (2024-2029)
Table 90. Asia-Pacific Myasthenia Gravis Treatment Sales by Region (2024-2029) & (US$ Million)
Table 91. Asia-Pacific Myasthenia Gravis Treatment Sales Market Share in Value by Region (2024-2029)
Table 92. Latin America Myasthenia Gravis Treatment Sales by Country (2018-2024) & (K Units)
Table 93. Latin America Myasthenia Gravis Treatment Sales Market Share in Volume by Country (2018-2024)
Table 94. Latin America Myasthenia Gravis Treatment Sales by Country (2018-2024) & (US$ Million)
Table 95. Latin America Myasthenia Gravis Treatment Sales Market Share in Value by Country (2018-2024)
Table 96. Latin America Myasthenia Gravis Treatment Sales by Country (2024-2029) & (K Units)
Table 97. Latin America Myasthenia Gravis Treatment Sales Market Share in Volume by Country (2024-2029)
Table 98. Latin America Myasthenia Gravis Treatment Sales by Country (2024-2029) & (US$ Million)
Table 99. Latin America Myasthenia Gravis Treatment Sales Market Share in Value by Country (2024-2029)
Table 100. Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2018-2024) & (K Units)
Table 101. Middle East and Africa Myasthenia Gravis Treatment Sales Market Share in Volume by Country (2018-2024)
Table 102. Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2018-2024) & (US$ Million)
Table 103. Middle East and Africa Myasthenia Gravis Treatment Sales Market Share in Value by Country (2018-2024)
Table 104. Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2024-2029) & (K Units)
Table 105. Middle East and Africa Myasthenia Gravis Treatment Sales Market Share in Volume by Country (2024-2029)
Table 106. Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2024-2029) & (US$ Million)
Table 107. Middle East and Africa Myasthenia Gravis Treatment Sales Market Share in Value by Country (2024-2029)
Table 108. Amneal Pharmaceuticals, Inc. Company Information
Table 109. Amneal Pharmaceuticals, Inc. Introduction and Business Overview
Table 110. Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product
Table 112. Amneal Pharmaceuticals, Inc. Recent Development
Table 113. Astellas Pharma, Inc. Company Information
Table 114. Astellas Pharma, Inc. Introduction and Business Overview
Table 115. Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Astellas Pharma, Inc. Myasthenia Gravis Treatment Product
Table 117. Astellas Pharma, Inc. Recent Development
Table 118. Avadel Pharmaceuticals PLC Company Information
Table 119. Avadel Pharmaceuticals PLC Introduction and Business Overview
Table 120. Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product
Table 122. Avadel Pharmaceuticals PLC Recent Development
Table 123. Bausch Health Companies Inc. Company Information
Table 124. Bausch Health Companies Inc. Introduction and Business Overview
Table 125. Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Bausch Health Companies Inc. Myasthenia Gravis Treatment Product
Table 127. Bausch Health Companies Inc. Recent Development
Table 128. CSL Behring Company Information
Table 129. CSL Behring Introduction and Business Overview
Table 130. CSL Behring Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. CSL Behring Myasthenia Gravis Treatment Product
Table 132. CSL Behring Recent Development
Table 133. CuraVac, Inc. Company Information
Table 134. CuraVac, Inc. Introduction and Business Overview
Table 135. CuraVac, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. CuraVac, Inc. Myasthenia Gravis Treatment Product
Table 137. CuraVac, Inc. Recent Development
Table 138. Argenx SE Company Information
Table 139. Argenx SE Introduction and Business Overview
Table 140. Argenx SE Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Argenx SE Myasthenia Gravis Treatment Product
Table 142. Argenx SE Recent Development
Table 143. GlaxoSmithKline plc Company Information
Table 144. GlaxoSmithKline plc Introduction and Business Overview
Table 145. GlaxoSmithKline plc Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. GlaxoSmithKline plc Myasthenia Gravis Treatment Product
Table 147. GlaxoSmithKline plc Recent Development
Table 148. Immunovant, Inc. Company Information
Table 149. Immunovant, Inc. Introduction and Business Overview
Table 150. Immunovant, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 151. Immunovant, Inc. Myasthenia Gravis Treatment Product
Table 152. Immunovant, Inc. Recent Development
Table 153. Mitsubishi Tanabe Pharma Corp. Company Information
Table 154. Mitsubishi Tanabe Pharma Corp. Introduction and Business Overview
Table 155. Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 156. Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product
Table 157. Mitsubishi Tanabe Pharma Corp. Recent Development
Table 158. Novartis AG Company Information
Table 159. Novartis AG Introduction and Business Overview
Table 160. Novartis AG Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 161. Novartis AG Myasthenia Gravis Treatment Product
Table 162. Novartis AG Recent Development
Table 163. Takeda Pharmaceutical Co., Ltd. Company Information
Table 164. Takeda Pharmaceutical Co., Ltd. Introduction and Business Overview
Table 165. Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 166. Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product
Table 167. Takeda Pharmaceutical Co., Ltd. Recent Development
Table 168. UCB Pharma Company Information
Table 169. UCB Pharma Introduction and Business Overview
Table 170. UCB Pharma Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 171. UCB Pharma Myasthenia Gravis Treatment Product
Table 172. UCB Pharma Recent Development
Table 173. AstraZeneca Company Information
Table 174. AstraZeneca Introduction and Business Overview
Table 175. AstraZeneca Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 176. AstraZeneca Myasthenia Gravis Treatment Product
Table 177. AstraZeneca Recent Development
Table 178. F. Hoffmann-La Roche Ltd Company Information
Table 179. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 180. F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 181. F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Product
Table 182. F. Hoffmann-La Roche Ltd Recent Development
Table 183. Key Raw Materials Lists
Table 184. Raw Materials Key Suppliers Lists
Table 185. Myasthenia Gravis Treatment Market Trends
Table 186. Myasthenia Gravis Treatment Market Drivers
Table 187. Myasthenia Gravis Treatment Market Challenges
Table 188. Myasthenia Gravis Treatment Market Restraints
Table 189. Myasthenia Gravis Treatment Distributors List
Table 190. Myasthenia Gravis Treatment Downstream Customers
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. Myasthenia Gravis Treatment Product Picture
Figure 2. Global Myasthenia Gravis Treatment Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Myasthenia Gravis Treatment Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Myasthenia Gravis Treatment Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Monoclonal Antibodies
Figure 6. Global Monoclonal Antibodies Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Intravenous Immunoglobulin
Figure 8. Global Intravenous Immunoglobulin Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of Other
Figure 10. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Global Myasthenia Gravis Treatment Sales by Type (2018-2029) & (US$ Million)
Figure 12. Global Myasthenia Gravis Treatment Sales Market Share by Type in 2022 & 2029
Figure 13. North America Myasthenia Gravis Treatment Sales Market Share in Volume by Type in 2022
Figure 14. North America Myasthenia Gravis Treatment Sales Market Share in Value by Type in 2022
Figure 15. Europe Myasthenia Gravis Treatment Sales Market Share in Volume by Type in 2022
Figure 16. Europe Myasthenia Gravis Treatment Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Myasthenia Gravis Treatment Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Myasthenia Gravis Treatment Sales Market Share in Value by Type in 2022
Figure 19. Latin America Myasthenia Gravis Treatment Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Myasthenia Gravis Treatment Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Myasthenia Gravis Treatment Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Myasthenia Gravis Treatment Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Myasthenia Gravis Treatment Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Myasthenia Gravis Treatment Revenue in 2022
Figure 25. Myasthenia Gravis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 26. Product Picture of Hospital
Figure 27. Global Hospital Sales YoY Growth (2018-2029) & (K Units)
Figure 28. Product Picture of Specialist Clinic
Figure 29. Global Specialist Clinic Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Product Picture of Other
Figure 31. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Global Myasthenia Gravis Treatment Sales by Application (2018-2029) & (US$ Million)
Figure 33. Global Myasthenia Gravis Treatment Sales Market Share by Application in 2022 & 2029
Figure 34. North America Myasthenia Gravis Treatment Sales Market Share in Volume by Application in 2022
Figure 35. North America Myasthenia Gravis Treatment Sales Market Share in Value by Application in 2022
Figure 36. Europe Myasthenia Gravis Treatment Sales Market Share in Volume by Application in 2022
Figure 37. Europe Myasthenia Gravis Treatment Sales Market Share in Value by Application in 2022
Figure 38. Asia-Pacific Myasthenia Gravis Treatment Sales Market Share in Volume by Application in 2022
Figure 39. Asia-Pacific Myasthenia Gravis Treatment Sales Market Share in Value by Application in 2022
Figure 40. Latin America Myasthenia Gravis Treatment Sales Market Share in Volume by Application in 2022
Figure 41. Latin America Myasthenia Gravis Treatment Sales Market Share in Value by Application in 2022
Figure 42. Middle East and Africa Myasthenia Gravis Treatment Sales Market Share in Value by Application in 2022
Figure 43. Key Raw Materials Price
Figure 44. Myasthenia Gravis Treatment Manufacturing Cost Structure
Figure 45. Myasthenia Gravis Treatment Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries